S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
Free Trial
NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free CNCE Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$8.37
▼
$8.37
50-Day Range
$8.33
▼
$8.40
52-Week Range
$2.66
▼
$8.55
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CNCE stock logo

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

CNCE Stock News Headlines

April 7, 2024 | nytimes.com
The Best Bag to Bring to a Concert Is Actually a Running Belt
April 1, 2024 | au.news.yahoo.com
Teresa Giudice and Her Lookalike Daughters Glam Up for Nicki Minaj Concert: ‘New Jersey Takes Gag City’
April 19, 2024 | Stansberry Research (Ad)
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
March 30, 2024 | msn.com
Video: Pharma boss apologises after pill linked to five deaths and over 100 hospitalisations
October 28, 2023 | nypost.com
NFL pushed networks to air Taylor Swift concert film promos — for free
October 2, 2023 | msn.com
Beyoncé 'Renaissance' Movie Tickets and How To See Concert Film in Theaters
September 15, 2023 | usatoday.com
Taylor Swift 'overjoyed' to release Eras Tour concert movie: How to watch
September 12, 2023 | usatoday.com
Bruce Springsteen forced to postpone Philadelphia concerts with E Street Band due to illness
April 19, 2024 | Stansberry Research (Ad)
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
August 7, 2023 | usatoday.com
Miranda Lambert scolds fans for taking selfies during her concert: 'I don't like it'
August 6, 2023 | usatoday.com
The worst people at concerts, from self-involved selfie takers to nonstop filmers
July 25, 2023 | bbc.co.uk
Highlights from King Charles III Coronation concert
July 17, 2023 | usatoday.com
Fan throws bag of ashes at Pink during tour concert
July 4, 2023 | ca.style.yahoo.com
Birds Papaya stuns fans in Shania Twain-inspired outfit for concert
May 7, 2023 | bbc.com
How to watch the Coronation and Coronation Concert on BBC TV and iPlayer and listen on radio and BBC Sounds
May 4, 2023 | bbc.co.uk
Ticket ballot for the Coronation Concert
March 26, 2023 | msn.com
Who is Florence Price? Find out at a free Philadelphia Orchestra concert Saturday
February 15, 2023 | finance.yahoo.com
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
February 6, 2023 | markets.businessinsider.com
Analysts Are Neutral on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Concert Pharma (CNCE)
January 30, 2023 | benzinga.com
Moore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law Firm
January 23, 2023 | finance.yahoo.com
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
January 22, 2023 | msn.com
5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma
January 20, 2023 | finance.yahoo.com
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
January 20, 2023 | marketwatch.com
CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
January 19, 2023 | benzinga.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Concert Pharmaceuticals, Inc. (CNCE)
January 19, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma
January 19, 2023 | marketwatch.com
Concert Pharmaceuticals Shares Rally on Takeover by Sun >CNCE
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNCE
CUSIP
N/A
CIK
1367920
Web
www.concertpharma.com
Phone
(781) 860-0045
Fax
302-636-5454
Employees
64
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-80,050,000.00
Net Margins
N/A
Pretax Margin
-300,735.69%
Return on Equity
-109.43%
Return on Assets
-76.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.03
Quick Ratio
9.03

Sales & Book Value

Annual Sales
$32.58 million
Price / Sales
12.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.24 per share
Price / Book
2.58

Miscellaneous

Outstanding Shares
47,940,000
Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

CNCE Stock Analysis - Frequently Asked Questions

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million. During the same quarter last year, the firm posted ($0.60) earnings per share.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

This page (NASDAQ:CNCE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends